Parties Agree to Extend Research to Focus on
Medicinal Crop
MONTREAL, March 26, 2020 /CNW/ - Mondias Natural
Products Inc. (TSXV: NHP) (the "Company" or
"Mondias") specializing in evidence-based natural products
for the healthcare, bio-agriculture and functional beverages
markets today announces that the Company has successfully completed
the initial research studies previously announced with Premier
Tech. Premier Tech efficacy results for CELEXT07 confirm that
the product has potential as a biocontrol and bio-stimulant
agent. As part of the research agreement, Premier Tech has
shared study results with Mondias and both parties have completed
the 180-day exclusivity period. In addition, both parties
have agreed to extend their research collaboration to confirm
Mondias' results and protocol on the use of CELEXT07 as a
bio-stimulant in medicinal crops under greenhouse conditions.
![Logo: Mondias Natural Products Inc. (CNW Group/Mondias Natural Products Inc.) Logo: Mondias Natural Products Inc. (CNW Group/Mondias Natural Products Inc.)](https://mma.prnewswire.com/media/1137849/Mondias_Natural_Products_Inc__Mondias_Announces_Successful_Compl.jpg)
Mondias CEO Dr. Patrick Frankham
stated that "these results confirm that CELEXT07 is a versatile and
robust organic agriculture product and that the previous data
generated by our CSO Dr. Samsatly and his team in collaboration
with the McGill University Faculty of
Agricultural and Environmental Sciences are highly reproducible as
reported by our colleagues at Premier Tech." Dr. Frankham
added that "the Company is positioning CELEXT07 as a commercial
product to initiate product sales including ongoing discussions
with potential partners. Given our prior experience with cannabis
plants and the time to market this represents the best opportunity
to monetize the product."
Dr. Jamil Samsatly, Mondias CSO stated that "over the past 6
months, we have continued to advance our agricultural research and
developed commercial application protocols for the use of CELEXT07
in various crops." Dr. Samsatly also added that "we have
initiated MITACS grant funded research and we have expanded our
pipeline of novel organic plant biocontrol and bio-stimulants."
CELEXT07 Target Markets in Canada
As of 2018, there was an
estimated 11M square feet of cannabis
greenhouse in Canada and an
eligible 59M, 53M, 39M square
feet of greenhouse tomatoes, peppers and cucumbers in the
country. According to Health Canada data there are an estimated 29,193
individuals registered for personal and designated cultivation of
cannabis for their own medical purposes at the end of September
2019.
About Mondias Natural Products Inc.
Mondias
specializes in the commercialization and development of
evidence-based botanical products for the healthcare,
bio-agriculture and organic markets. The company sells both oral
and topical botanical agents to help manage unmet medical needs
through its Holizen Laboratories division. Mondias is also
developing botanical-based specialty fertilizers for use on
household plants, lawns and golf courses and in urban gardens,
nurseries, commercial greenhouses and to indoor cannabis growers,
in collaboration with McGill's Faculty
of Agricultural and Environmental Sciences.
For more information, visit: www.mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than statements of historical fact, that address activities,
events or developments that the Company believes, expects or
anticipates will or may occur in the future (including, without
limitation, statements regarding potential acquisitions and
financings) are forward-looking statements. Forward-looking
statements are generally identifiable by the use of the words
"may", "will", "should", "continue", "expect", "anticipate",
"estimate", "believe", "intend", "plan" or "project" or the
negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond the
Company's ability to control or predict, that may cause the actual
results of the Company to differ materially from those discussed in
the forward-looking statements. Factors that could cause actual
results or events to differ materially from current expectations
include the Company's inability to obtain sufficient financing to
execute its business plan; competition; regulation; anticipated and
unanticipated costs and delays; the success of the Company's
research and development strategies; the ability to obtain orphan
drug status; the applicability of the discoveries made; the
successful and timely completion and uncertainties related to the
regulatory approval process; the timing of clinical trials; the
timing and outcomes of regulatory or intellectual property
decisions; and other risks disclosed in the Company's public
disclosure record on file with the relevant securities regulatory
authorities. Although the Company has attempted to identify
important factors that could cause actual results or events to
differ materially from those described in forward-looking
statements, there may be other factors that cause results or events
not to be as anticipated, estimated or intended. Readers should not
place undue reliance on forward-looking statements. The
forward-looking statements in this news release are made as of the
date of this news release, and the Company does not undertake any
obligation to publicly update them to reflect new information or
subsequent events or otherwise except as required by applicable
securities legislation.
SOURCE Mondias Natural Products Inc.